Literature DB >> 2836416

The active site sulfhydryl of aconitase is not required for catalytic activity.

M C Kennedy1, G Spoto, M H Emptage, H Beinert.   

Abstract

Previous reports have demonstrated that aconitase has a single reactive sulfhydryl at or near the active site (Johnson, P. G., Waheed, A., Jones, L., Glaid, A. J., and Gawron, O. (1977) Biochem. Biophys. Res. Commun. 74, 384-389). On the basis of experiments with phenacyl bromide in which enzyme activity was abolished while substrate afforded protection, it was concluded that this group was an essential sulfhydryl. We have further examined the reactivity of this group and confirmed the result that, when reagents with bulky groups (e.g. N-ethylmaleimide or phenacyl bromide) modify the protein at the reactive sulfhydryl, activity is lost. However, when smaller groups, e.g. the SCH3 from methylmethanethiosulfonate or the CH2CONH2 from iodoacetamide, are introduced, there is only partial (50%) or no loss of activity. Experiments were performed to obtain evidence that these reagents are modifying the same residue. Methylmethanethio-sulfonate-treated enzyme showed an increase in the Km for citrate from 200 to 330 microM. EPR spectra were taken of the reduced N-ethylmaleimide- and iodoacetamide-modified enzyme in the presence of substrate. The former gave a spectrum typical of the substrate-free enzyme, while the spectrum of the latter was identical to enzyme with bound substrate. We, therefore, conclude that modification of this sulfhydryl affects activity by interfering with the binding of substrate to the active site and is not essential in the catalytic process.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2836416

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Reversible redox-dependent modulation of mitochondrial aconitase and proteolytic activity during in vivo cardiac ischemia/reperfusion.

Authors:  Anne-Laure Bulteau; Kathleen C Lundberg; Masao Ikeda-Saito; Grazia Isaya; Luke I Szweda
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-19       Impact factor: 11.205

2.  The pro-oxidant chromium(VI) inhibits mitochondrial complex I, complex II, and aconitase in the bronchial epithelium: EPR markers for Fe-S proteins.

Authors:  Charles R Myers; William E Antholine; Judith M Myers
Journal:  Free Radic Biol Med       Date:  2010-09-27       Impact factor: 7.376

3.  Mechanistic studies of the spore photoproduct lyase via a single cysteine mutation.

Authors:  Linlin Yang; Gengjie Lin; Renae S Nelson; Yajun Jian; Joshua Telser; Lei Li
Journal:  Biochemistry       Date:  2012-08-31       Impact factor: 3.162

4.  Inhibition of aconitase by alloxan and the differential modes of protection of glucose, 3-O-methylglucose, and mannoheptulose.

Authors:  S Lenzen; M Mirzaie-Petri
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-11       Impact factor: 3.000

5.  Molecular cloning of the yeast mitochondrial aconitase gene (ACO1) and evidence of a synergistic regulation of expression by glucose plus glutamate.

Authors:  S P Gangloff; D Marguet; G J Lauquin
Journal:  Mol Cell Biol       Date:  1990-07       Impact factor: 4.272

6.  Exposure of aconitase to smoking-related oxidants results in iron loss and increased iron response protein-1 activity: potential mechanisms for iron accumulation in human arterial cells.

Authors:  Jihan Talib; Michael J Davies
Journal:  J Biol Inorg Chem       Date:  2016-02-02       Impact factor: 3.358

7.  Carbonylation of mitochondrial aconitase with 4-hydroxy-2-(E)-nonenal: localization and relative reactivity of addition sites.

Authors:  Qingyuan Liu; David C Simpson; Scott Gronert
Journal:  Biochim Biophys Acta       Date:  2013-03-18

8.  The PrpF protein of Shewanella oneidensis MR-1 catalyzes the isomerization of 2-methyl-cis-aconitate during the catabolism of propionate via the AcnD-dependent 2-methylcitric acid cycle.

Authors:  Christopher J Rocco; Karl M Wetterhorn; Graeme S Garvey; Ivan Rayment; Jorge C Escalante-Semerena
Journal:  PLoS One       Date:  2017-11-16       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.